Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.

Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL.

Am J Drug Alcohol Abuse. 2009;35(2):68-72. doi: 10.1080/00952990802585406.

2.

Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.

Vicknasingam B, Mazlan M, Schottenfeld RS, Chawarski MC.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):44-9. doi: 10.1016/j.drugalcdep.2010.03.014. Epub 2010 May 15.

PMID:
20478668
3.

Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG.

Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000.

PMID:
20450242
4.

Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.

Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.

PMID:
20450243
5.

The diversion and injection of a buprenorphine-naloxone soluble film formulation.

Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, White N, Degenhardt L.

Drug Alcohol Depend. 2014 Mar 1;136:21-7. doi: 10.1016/j.drugalcdep.2013.12.005. Epub 2014 Jan 8.

PMID:
24461476
6.

A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.

Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.

Addiction. 2012 Jan;107(1):142-51. doi: 10.1111/j.1360-0443.2011.03577.x. Epub 2011 Oct 12.

PMID:
21749526
7.

Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.

Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND.

J Addict Med. 2011 Sep;5(3):175-80. doi: 10.1097/ADM.0b013e3182034e31.

8.
9.

Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.

Häkkinen M, Heikman P, Ojanperä I.

Forensic Sci Int. 2013 Oct 10;232(1-3):11-5. doi: 10.1016/j.forsciint.2013.06.017. Epub 2013 Jul 19.

PMID:
24053859
10.

The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.

Mammen K, Bell J.

Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405. Review.

PMID:
19708849
11.

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.

Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD.

Addiction. 2010 Apr;105(4):709-18. doi: 10.1111/j.1360-0443.2009.02843.x. Erratum in: Addiction. 2010 Jul;105(7):1332.

12.

Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.

Degenhardt L, Larance BK, Bell JR, Winstock AR, Lintzeris N, Ali RL, Scheuer N, Mattick RP.

Med J Aust. 2009 Aug 3;191(3):161-5.

PMID:
19645647
13.

Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Montesano F, Zaccone D, Battaglia E, Genco F, Mellace V.

Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.

PMID:
20450241
14.

Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.

Larance B, Degenhardt L, Lintzeris N, Bell J, Winstock A, Dietze P, Mattick R, Ali R, Horyniak D.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):265-73. doi: 10.1016/j.drugalcdep.2011.04.002. Epub 2011 May 12.

PMID:
21565452
15.

Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.

Wong A, Macleod D, Robinson J, Koutsogiannis Z, Graudins A, Greene SL.

Clin Toxicol (Phila). 2015;53(8):815-8. doi: 10.3109/15563650.2015.1060486. Epub 2015 Jun 25.

PMID:
26109423
16.

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

Alho H, Sinclair D, Vuori E, Holopainen A.

Drug Alcohol Depend. 2007 Apr 17;88(1):75-8. Epub 2006 Oct 19.

PMID:
17055191
17.

Case series of buprenorphine injectors in Kuala Lumpur, Malaysia.

Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL.

Am J Drug Alcohol Abuse. 2008;34(4):511-7. doi: 10.1080/00952990802122259.

PMID:
18584580
18.

Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners.

Springer SA, Qiu J, Saber-Tehrani AS, Altice FL.

PLoS One. 2012;7(5):e38335. doi: 10.1371/journal.pone.0038335. Epub 2012 May 31.

19.

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP.

Psychopharmacology (Berl). 1999 Jan;141(1):37-46.

PMID:
9952063
20.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
Items per page

Supplemental Content

Write to the Help Desk